MedPath

Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate and calcium carbonate on FGF23 in hemodialysis patients

Not Applicable
Conditions
Chronic kidney disease
Registration Number
JPRN-UMIN000006333
Lead Sponsor
Juntendo University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) Malignancy of any type at enrollment 2) History of hypersensitivity to any of the ingredients of Lanthanum carbonate or Calcium carbonate 3) Severe hepatic dysfunction 4) Active digestive ulcer, ulcerative colitis, Crohn's disease and constriction of intestine 5) Pregnant or possibly pregnant women 6) Women on lactation 7) Ineligible patients according to the investigator's judgment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change of serum FGF23 levels
Secondary Outcome Measures
NameTimeMethod
Serum phosphate level achievement rate as defined by the JSDT guideline Safety
© Copyright 2025. All Rights Reserved by MedPath